News, As Huge As It Gets, From Hepion Pharma $2.10.
Long-Term Horizon, Long Only, Biotech, Special Situations
Seeking Alpha Analyst Since 2008
Roland Rick Perry is the Managing Director of Institutional Analyst Inc. (IA), an independent investment research firm, as well as editor of nine industry-specific investment reviews.
One of the top one-mile runners in history to come out of the Chicago area, he attended Southern Illinois University, Loyola of Chicago and UCLA on track scholarships, achieving an Olympic Qualifying time in the late 70's, right in time for the Olympic boycott in 1980.
Roland began his career on the floor of the Chicago Board Options Exchange (CBOE) as a runner in 1974 while in high school. He later worked for a number of well-respected investment banking firms such as Merrill Lynch, Paine Webber, AG Becker Paribas and Drexel Burnham Lambert, prior to launching his own firm in 1995.
He is the founder of the Chicago Stock & Bond Club, Morgan & Weed and Blank Check Capital Corp., which participated in Wall Street’s first “Ultra Mini™” blank check (SPAC) offering, as President of Life Sciences Opportunities Inc., which successfully merged with Beverly Hills-based “Dr Tattoff” the leading Tattoo removal company in the U.S., with over 250,000 treatments on more than 25,000 patients.
Mr. Perry has been quoted and/or interviewed in the New York Times, the Los Angeles Times, CBS MarketWatch, South China Morning Post, the London Register, the UK Register and featured in Australia's ABC televised broadcast Lateline, and in a featured segment piece on National Enquirer TV.
IA is a leading publisher of news, perspective, and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm works with small-cap companies which have products and/or services which can best be described as "best of breed." To align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in their client companies.
Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY.
Industries covered include:
Patent Monetization (on hold)
Marine Exploration (on hold)
Restaurants (on hold)
Blockchain (of course, but with major trepidation)
BDC's and Private Equity
Blanket disclaimer for all of our postings: Important Distinction #1. First and foremost the Watch List is just that. A watch list. It is not a buy list. Meaning that there will be no buys or sale recommendations issued by the various Reviews. If this was a buy list, you can rest assured that we would crank up our Public Relations arm into high gear, full speed ahead and damn the torpedoes to make everyone know just how brilliant we were when we issued the original Watch List in 1998 with the average stock gaining 157% the first year.. Interviews on CNBC, articles in Barron's and accolades in the Wall Street Journal--the only thing we love more than money is praise and fame--but it just isn't going to happen. What the Reviews are...is a "news aggregation service". With the advent of the Internet, everyone knows what that term means. What it means to us is the following: We will follow the progress of as many industry specific related publicly traded stocks as humanly possible (The large, the small and the minuscule) and advise you of when they have reported news. As a subscriber to any of our Reviews, this means you will be able to broadly follow an entire industry right from a single e-mail. We will report who released news and point (with hyperlinks) to where the news can be found. We try to use Yahoo! Finance and Seeking Alpha as extensively as possible so we don't send you all over cyberspace. We love Yahoo and Seeking Alpha, you will too. Any decisions as to buy or sell, however, are strictly up to you. Which leads to important distinction #2. How do we get paid? The Reviews are owned by a Public Relations firm (Institutional Analyst Inc.) that specializes in getting (or creating) coverage for publicly traded companies.
As such, is important to note that anytime we say anything about a company, it is because the company is a client of our parent company, or because we would like them to be a client of our parent company. In a nutshell, you can throw out any thoughts of us being even a little bit impartial. It just ain't gonna happen. We love everyone. Institutional Analyst Inc. is an independent research and investor-relations consulting firm that publishes investment-research reports such as The Reviews on independently selected companies. While it is its intent to identify and research companies that it believes might prove to be profitable investments, we have no control over the eventual outcome.
The Review is not liable for any investment decisions by its readers. Neither The Reviews nor any report published by Institutional Analyst Inc., represent a solicitation to buy or sell the securities discussed within the report. It is strongly recommended that any purchase or sale decisions be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. The information contained herein is provided as an information service only and is based upon sources deemed reliable, but not guaranteed by The Reviews. Past performance of previously featured companies does not guarantee the future success of any currently featured or mentioned company. The information contained herein is subject to change without notice, and The Reviews assumes no responsibility to update the information in this or any report published. Use of this or any report published by The Review may be subject to the applicable rules of certain self-regulatory organizations and the securities mentioned herein, which are traded Over The Counter, and may not be cleared for sale in certain states. Institutional Analyst Inc and/or its employees, officers, affiliates or members of their families may have long or short positions in any of the securities discussed in this or other reports published herein (and/or options or warrants relating thereto) and may purchase and or sell these securities, options or warrants from time to time in the open market or otherwise.
Institutional Analyst Inc may derive compensation through research services and subscriptions and/or investor-relations consulting from the companies featured or mentioned in its reports. Write or call Institutional Analyst Inc for disclosure details as required by Rule 17b as it relates to individual issues. Institutional Analyst Inc., In no event, shall The Reviews report be liable for direct, indirect, incidental or consequential damages resulting from the use of this information. The Reviews shall be indemnified and held harmless from any actions, claims, proceedings or liabilities with respect to the information herein. Institutional Analyst Inc is not a securities broker-dealer, investment advisor or a securities exchange and is not registered as such with the Securities and Exchange Commission nor any state securities regulatory authority. Readers of this e-mail newsletter should recognize that the Reviews are only providing a delivery service to electronically transmit information to potential investors. In this respect, the Reviews are no different than the provider of any other delivery service such as the United States Post Office or any other express delivery service. Accordingly, investors should be aware that the Reviews have not evaluated nor investigated any of the companies listed in this e-mail to determine their merit or the risk of investment in any such company. The Reviews do not endorse any company listed herein and the Reviews do not represent that the information contained in any offering documents states all material facts or does not omit a material fact necessary to make the statements therein not misleading. Roland@institutionalanalyst@com
For specific company disclaimer, please visit any of our websites about disclaimers where we have been compensated are on each blog right-up-front in big print, on each research report written and in the general disclaimer section. We have nothing to hide, our disclaimers are everywhere. As the majority of our compensation is in restricted stock, the better our clients perform (which we have no control over), the better we are compensated and vice versa. This is in sharp contrast to firms which only accept cash as compensation, and who really couldn't care less how the stock performs, as long as their check keeps coming in. We believe this puts us on the same page as shareholders and our readers because we are in fact shareholders.
- Early Safety Numbers Out.
- Early Efficacy Numbers Out.
- Data Safety Monitoring Board Gives Go Ahead.
- Closed $34 Million Secondary.
Of course, approval news is the ultimate “as huge as it gets” news.
But at this stage in the development of any biotechnology start-up, these early-indications of ‘is it safe’ and does it ‘appear to work’ from Hepion, should have the mouths of any self-respecting early-stage biotechnology investor watering. Or send a chill up their spine. It sent a chill up our spine..
This indeed is what speculating in biotech stocks is all about. First, follow news about safety. Then follow news about safety in comparison to benefits derived. Then follow early news of potential benefits. How good are the benefits and how many people (percentage-wise) have benefitted?
Depending on an investor’s risk profile, one can invest any time as the onion is peeled. An investor can invest at the first peel (pre-clinical trials), or wait anywhere up until the final peel (Phase III trials), or even wait until after the final peel (actual FDA approval).
The danger of investing during the peeling process is if they discover the onion is rotten, then it will probably be too late to get out. The danger of waiting for final approval – is when any one of a dozen multi-billion Pharma’s, who are also watching the onion being peeled – decide enough evidence is enough and they acquire the start-up before final FDA approval. And potentially save $100’s of millions in an acquisition cost. Then it of course it will be too late to get in. As in “damn, I just knew I shouldn’t have waited after reading about the good early indications.”
Yesterday Hepion Pharma announced early results of safety and efficacy (does it work) of their lead treatment, CRV431.
As a reminder, CRV431 is a treatment for fatty-liver. Get a quick education here in a news archive we are building: Hepion Pharma (HEPA): News Archive
First, their independent Data Safety Monitoring Board (DSMB) after evaluating the safety and tolerability data of a low dose (75mg) of CRV431 said “keep going” on their Phase 2a ‘AMBITION’ clinical trial.
Read More: Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation.
Second and more important was they announced significant early results in the liver chemistry they were hoping for – occurred rapidly and were sustained throughout the 28 days of dosing.
Dr. Stephen Harrison, Hepion’s Consultant Medical Director, commented, “The reductions in the liver chemistry tests, ALT and AST, occurred rapidly and were sustained throughout the 28 days of dosing. These reductions began to return to baseline once the patients stopped taking CRV431 at the end of the study, indicative of a drug effect. As such, these early signals are supportive of positive actions on liver health in a short period of time with the low dose of CRV431, and we eagerly look forward to evaluating the fibrosis biomarkers, as well as the higher dose of CRV431, in the second cohort.”
Biomarkers of efficacy, including declines in alanine aminotransferase (“ALT”) and aspartate aminotransferase (“AST”) from baseline to day 28 were observed, with mean declines of 18.4% and 12.1%, respectively.
If that doesn’t send a chill – not much else will. Investors took note and the shares went on a tear trading from a low of $1.91 the day before, to a high of $2.74 with 13 million shares trading hands. Boo-ya!
READ MORE: Hepion Pharmaceuticals Announces Positive Top Line Data
The next peel to be unveiled will be the results from larger dosing of CRV431 or at 225mg. Patient dosing is expected to be completed in Q1-2021.
Should you make Hepion Pharma your last wise decision for 2020? Only time will tell.
Stare at this chart for a moment. We’re guessing it won’t look anything like this at this time next year.
Adding Hepion Pharma (HEPA) $1.73 to Watch List.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays, increased costs and funding shortages caused by the COVID-19 pandemic; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2019 and other periodic reports filed with the Securities and Exchange Commission. Client, we were compensated ten thousand dollars for initiating coverage and may receive additional compensation for ongoing progress coverage and reporting.
Analyst's Disclosure: I am/we are long HEPA.
Client, see report for disclaimer and disclosure details.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.